Table 2 Correlation between the clinicopathologic variables and NγLR level in HCC patients (training cohort, n = 463 and validation cohort, n = 261). NγLR, neutrophil cell count times γ-glutamyl transpeptidase to lymphocyte count ratio; HBsAg, hepatitis B surface antigen; BCLC, barcelona-clinic liver cancer; AFP, alpha-fetoprotein; ALT, alanine aminotransferase; SII, systemic immune-inflammation index; ALRI, aspartate transaminase to lymphocyte ratio index; NAs, nucleoside analogues.

From: A novel prognostic index—neutrophil times γ-glutamyl transpeptidase to lymphocyte ratio (NγLR) predicts outcome for patients with hepatocellular carcinoma

Variables

NγLR level

Training cohort

Validation cohort

≤103.6

>103.6

P value

≤103.6

>103.6

P value

Gender

Female

32

30

0.006

21

17

0.020

Male

135

266

79

144

Age (years)

≤55

107

200

0.445

63

114

0.189

>55

60

96

37

47

HBsAg

Negative

24

44

0.885

22

23

0.109

Positive

143

252

78

138

Tumor size

≤8 cm

145

149

<0.001

94

93

<0.001

>8 cm

22

147

6

68

Tumor number

Single

132

195

0.003

84

116

0.027

Multiple

35

101

16

45

Tumor differentiation

I- II

132

109

<0.001

78

54

<0.001

III- IV

35

187

22

107

Vascular invasion

Absent

158

223

<0.001

92

108

<0.001

Present

9

73

8

53

BCLC stage

0 + A

125

127

<0.001

76

69

<0.001

B + C

42

169

24

92

Early recurrence

Absent

135

206

0.008

62

120

0.032

Present

32

90

38

41

AFP (ng/ml)

≤20

59

77

0.035

46

46

0.004

>20

108

219

54

115

ALT (U/L)

≤40

122

103

<0.001

72

67

<0.001

>40

45

193

28

94

SII (×109/L)

≤330

122

101

<0.001

62

52

<0.001

>330

45

195

38

109

ALRI

≤25.2

129

103

<0.001

69

75

<0.001

>25.2

38

193

31

86

Use of NAs

Absent

89

221

<0.001

58

123

0.012

Present

45

48

23

21

Back to article page